Review discusses ACSL4 metabolic switch potential in hepatocellular carcinoma therapy strategies
Review suggests metabolic switch concept may guide future liver cancer treatments
This mini-review examines the role of ACSL4 as a metabolic switch rather than a static oncogenic factor in hepatocellular carcinoma. The aut…
Viewing a liver cancer protein as a metabolic switch could guide new therapies that boost a specific cell death process to fight tumors.
Immune checkpoint inhibitor regimens improve survival versus tyrosine kinase inhibitor monotherapies in advanced hepatocellular carcinoma
The Liver Cancer Treatment That Works Better Depending on Your History
This systematic review and meta-analysis of seventeen studies evaluated immune checkpoint inhibitor (ICI)-based regimens versus tyrosine kin…
Immunotherapy beats older drugs for advanced liver cancer, especially when hepatitis B caused the disease, but benefits depend on your liver…
Regorafenib plus nivolumab in second-line hepatocellular carcinoma showed safety and survival signals in a Phase IIa trial.
Some Liver Cancer Patients Are Surviving Far Longer on a New Drug Combination
This Phase IIa trial evaluated regorafenib plus nivolumab as an add-on therapy in patients with hepatocellular carcinoma who had progressed …
A combination of regorafenib and nivolumab showed unexpectedly long survival in people with advanced liver cancer who had already exhausted …
Network meta-analysis finds similar overall survival for three HCC regimens
Three drugs show similar survival for unresectable liver cancer patients
A network meta-analysis of 11 studies in unresectable hepatocellular carcinoma found no statistically significant differences in overall sur…
Three drugs show similar survival for unresectable liver cancer patients, offering patients clearer choices without proving one option is de…